Ore Pharmaceuticals acquired the development rights for romazarit through its partnership with Roche, where it was initially developed as an anti-inflammatory compound and had reached Phase II clinical
The proposal is said to represent a 20% premium above Endocare’s closing stock price on August 6, 2008. James Whittenburg, president and CEO of HealthTronics, said: “After carefully
According to the company, this expands the initial CE Mark approval of the Mirasol pathogen reduction technology (PRT) system for platelets granted in October 2007. The company can
The patent covers a family of hexapeptide antimicrobial agents, including HB1345, for use as broad spectrum topical anti-infectives. HB1345 will be developed initially for dermatological indications such acne,
Upon the closing of the acquisition, all remaining outstanding shares of Barrier common stock, other than those held by stockholders who properly perfect appraisal rights under Delaware law,
The net proceeds to Incyte from the offering are approximately $101.8 million, after deducting the underwriting discount and estimated offering expenses. The company intends to use the net
Dome’s customers include global picture archiving and communication systems (PACS) original equipment manufacturer (OEM) suppliers and medical information technology resellers to healthcare providers. John Murphy, president and CEO
According to the joint venture (JV), Basic Solutions will offer mobile cardiac stress testing and cardiac imaging services from Lumar’s diagnostic medical imaging facility in Houston, Texas. Graham
The agreement also provides Mylan with a right of first refusal for additional oral contraceptive products and certain additional markets, including Australia and Japan, where Mylan has a
Mr Kernaghan joined PharMerica in April 2008 as vice president of information services. Prior to joining PharMerica, Mr Kernaghan served seven years as senior vice president and CIO
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.